1. |
|
|
2. |
|
|
3. |
- Saglio, Giuseppe, et al.
(författare)
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
- 2010
-
Ingår i: The New England journal of medicine. - 1533-4406. ; 362:24, s. 2251-9
-
Tidskriftsartikel (refereegranskat)abstract
- Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase.
|
|